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Introduction {#sec001}
============

The HIV-1 structural protein Gag is produced in the cytoplasm and traffics to the plasma membrane where it assembles into a viral particle that buds from the host membrane \[[@ppat.1008646.ref001]\]. Gag is a polyprotein consisting of the Matrix (MA), Capsid (CA), Spacer 1 (SP1), Nucleocapsid (NC), Spacer 2 (SP2), and p6 domains \[[@ppat.1008646.ref001],[@ppat.1008646.ref002]\]. During assembly, the Gag protein assembles into an \'immature\' hexagonal lattice, driven primarily by interactions involving the CA and SP1 domains \[[@ppat.1008646.ref001],[@ppat.1008646.ref003]\]. The C-terminal CA and SP1 domains contain an alpha-helix that forms a six-helix bundle with the other Gag proteins in the hexamer \[[@ppat.1008646.ref004],[@ppat.1008646.ref005]\]. This bundle is important in formation and stabilization of the immature lattice \[[@ppat.1008646.ref004],[@ppat.1008646.ref005]\]. During or shortly after budding from the cell, the viral protease cleaves the Gag polyprotein into its constitutive components, which separates CA from SP1 and eliminates the six-helix bundle \[[@ppat.1008646.ref001],[@ppat.1008646.ref006]\]. The liberated CA protein then assembles into a structurally distinct \'mature\' lattice, which forms the viral core \[[@ppat.1008646.ref001],[@ppat.1008646.ref007]\].

Early attempts to assemble full length HIV-1 Gag protein *in vitro* revealed that proper assembly required the presence of cell lysate \[[@ppat.1008646.ref008]\]. This pointed to an assembly co-factor that catalyzed viral assembly in cells. Further research revealed that inositol phosphates were sufficient to stimulate proper assembly, but the mechanistic basis for this effect was poorly understood \[[@ppat.1008646.ref003]\]. Recently, a Cryo-EM reconstruction of *in vivo*-produced immature HIV-1 particles revealed a small density above the CA-SP1 six-helix bundle that was coordinated by two rings of lysine residues, suggesting the presence of a negatively charged molecule inside the particle that helped stabilize the bundle \[[@ppat.1008646.ref004]\]. This evidence for such a molecule, in conjunction with previous data that inositol phosphates stimulate assembly, prompted further evaluation of the role of inositol phosphates as HIV-1 assembly co-factors \[[@ppat.1008646.ref003],[@ppat.1008646.ref008],[@ppat.1008646.ref009]\]. In particular, Inositol hexakisphosphate (I(1,2,3,4,5,6)P~6~ or IP6), which is a hexagonal six-carbon ring with a negatively charged phosphate at each position, seemed like a likely match for the density identified in particles \[[@ppat.1008646.ref010]\].

In assembly experiments *in vitro*, the presence of IP6 was found to potently promote immature assembly and even to modulate whether particular Gag proteins assembled into immature or mature lattices \[[@ppat.1008646.ref010]\]. Mutation of the lysine residues in Gag believed to coordinate the negatively charged molecule made the Gag proteins 100-fold less responsive to IP6 in *in vitro* assembly reactions \[[@ppat.1008646.ref010]\]. When a crystal structure of the HIV-1 CA~CTD~SP1 protein in the presence of IP6 was solved, a density was observed associated with the six-helix bundle that precisely matched the density described in the *in vivo* Cryo-EM reconstruction \[[@ppat.1008646.ref004],[@ppat.1008646.ref010]\]. These biochemical and structural data strongly support the conclusion that the density observed in HIV-1 particles is indeed IP6, but the data could not reveal whether IP6 is an absolute requirement for HIV-1 assembly *in vivo*.

IP6 is found in mammalian cells at concentrations of 10-100uM \[[@ppat.1008646.ref011]\], and is synthesized by a series of host enzymes through a complex and not fully resolved process ([Fig 1A](#ppat.1008646.g001){ref-type="fig"}) \[[@ppat.1008646.ref012]--[@ppat.1008646.ref028]\]. The immediate precursor to IP6 is inositol pentakisphosphate (I(1,3,4,5,6)P~5~ or IP5), and the only enzyme known to catalyze the addition of the final 2-phosphate is inositol-pentakisphosphate 2-kinase (IPPK) \[[@ppat.1008646.ref012]--[@ppat.1008646.ref016]\]. IP5 was also shown to stimulate immature HIV-1 assembly *in vitro*, though not as robustly as IP6 \[[@ppat.1008646.ref010],[@ppat.1008646.ref029]--[@ppat.1008646.ref031]\]. In cells, several pathways have been described that lead to IP5 production, but all of those described in mammalian cells require the enzyme inositol-polyphosphate multikinase (IPMK) \[[@ppat.1008646.ref012],[@ppat.1008646.ref016]--[@ppat.1008646.ref020]\]. However, cells derived from a homozygous mouse embryo deficient in IPMK still produced residual levels of IP5 and IP6 through an unknown mechanism \[[@ppat.1008646.ref015],[@ppat.1008646.ref017]\]. Recently, a genetic screen performed to identify genes involved in necroptosis revealed that inositol phosphates IP5 or IP6 are required for this process \[[@ppat.1008646.ref021]\]. Importantly, the screen identified the genes *IPMK* and *inositol-tetrakisphosphate 1-kinase (ITPK1)* as being required for necroptosis, and cells lacking either of these genes were noticeably deficient in IP5 and IP6 \[[@ppat.1008646.ref021],[@ppat.1008646.ref022]\]. Thus, IPMK and ITPK1 likely cooperate in the production of IP5 in cells. Moreover, knockouts of the IPPK and IPMK genes have both been reported to reduce, but not abolish, the production of infectious HIV-1 particles *in vivo* \[[@ppat.1008646.ref010],[@ppat.1008646.ref029]--[@ppat.1008646.ref031]\].

![Knock-out of cellular genes leading to the production of IP6.\
(A) Inositol phosphate pathway in *H*. *sapiens*. Inositol-pentakisphosphate 2-kinase (IPPK) adds the sixth phosphate to position 2 of IP5 (yellow box). IP5 synthesis from I(1,3,4,5)P~**4**~ and I(1,3,4,6)P~**4**~ has not been fully resolved. Other abbreviations: phospholipase C (PLC), IP~**3**~3K (inositol-triphosphate 3-kinase), IPMK (inositol-polyphosphate multikinase), INPP5 (inositol-polyphosphate 5-phosphatase), and ITPK1 (inositol-tetrakisphosphate 1-kinase). (B-C) Chromatograms showing insertion-deletions of inositol-phosphate pathway KOs in HEK293FTs. Red bars delineate the 20-base pair guide RNA sequence used for CRISPR/Cas9 targeting. (B) KO of IPPK has a 10-base pair (bp) deletion. (C) KO of IPMK has three copies with 1- and 10-bp deletions and a 1-bp insertion.](ppat.1008646.g001){#ppat.1008646.g001}

Here, we sought to determine whether the presence of inositol phosphates IP6/IP5 are an absolute requirement for HIV-1 particle. To accomplish this, we developed a system to transiently deplete cells of both IP6 and IP5 and test the assembly competence of HIV-1 and various other retroviruses under these conditions. During the preparation of this manuscript, Mallery *et al*. \[[@ppat.1008646.ref031]\] published findings that IP5 can substitute for IP6 without loss of infectivity of the particles produced. In addition to their findings, we found that HIV-1 is absolutely dependent on the presence of IP6 or IP5 for viral production, but non-primate lentiviruses and viruses from retrovirus genera other than lentivirus are not. We further found that neither IP6 nor IP5 is required in viral target cells for successful HIV-1 infection.

Results {#sec002}
=======

IPMK contributes to IP6 synthesis and infectious virus production {#sec003}
-----------------------------------------------------------------

We previously showed that IP6 stimulates immature *in vitro* HIV-1 particle assembly \[[@ppat.1008646.ref010]\]. We further showed that knock out of IPPK, the only enzyme known to catalyze addition of the final phosphate in the generation of IP6 ([Fig 1A and 1B](#ppat.1008646.g001){ref-type="fig"}) \[[@ppat.1008646.ref012]--[@ppat.1008646.ref016]\], resulted in a drastic reduction in infectious HIV-1 particle production from cells \[[@ppat.1008646.ref010]\]. However, infectious particles were still produced from HEK293FT IPPK knockout (IPPK-KO) cells, albeit at a greatly reduced rate \[[@ppat.1008646.ref010]\]. There are three possible explanations for this partial phenotype. First, the cells could be continuing to produce low levels of IP6 through an unknown mechanism. Second, IP6 may enhance infectious HIV-1 particle production, but not strictly be required for it. Finally, IP5, the precursor to IP6 that can partially stimulate HIV-1 particle production *in vitro*, could substitute for IP6 in infectious particle production. To test the latter explanation, we attempted to generate a cell line that is deficient in both IP5 and IP6 production, in order to test if such a cell line would be completely deficient in infectious particle production. The enzyme inositol-polyphosphate multikinase (IPMK) has been reported to catalyze the penultimate step in IP6 production; thus, knockout of this enzyme would theoretically abolish IP5 and IP6 synthesis \[[@ppat.1008646.ref012],[@ppat.1008646.ref016]--[@ppat.1008646.ref022]\]. We used CRISPR/Cas9 with a guide RNA against *IPMK* \[[@ppat.1008646.ref032],[@ppat.1008646.ref033]\] to generate an isolated clonal IPMK knockout (IPMK-KO) cell line ([Fig 1C](#ppat.1008646.g001){ref-type="fig"}). The validated clonal IPMK-KO cell line was then compared to HEK293FT cells and the previously described IPPK-KO cell line (previously described in \[[@ppat.1008646.ref010]\]; sequence validations for selected clones shown in [Fig 1B and 1C](#ppat.1008646.g001){ref-type="fig"}).

First, we wanted to validate the loss of IP6 and IP5 in our IPPK-KO and IPMK-KO cells respectively. Using TiO~2~ extraction and 33% PAGE separation \[[@ppat.1008646.ref034],[@ppat.1008646.ref035]\], we found that the IPPK-KO cells had no detectable IP6, but a slightly elevated level of IP5 compared to HEK293FT cells ([Fig 2A--2C](#ppat.1008646.g002){ref-type="fig"}). From a functional standpoint, this confirms our KO. In contrast, the IPMK-KO cells had residual levels of both IP6 and IP5 ([Fig 2A--2C](#ppat.1008646.g002){ref-type="fig"}). This finding is consistent with a previous report that showed that cells from an IPMK knockout embryo were also shown to produce low levels of IP5 and IP6 through an unknown mechanism \[[@ppat.1008646.ref021],[@ppat.1008646.ref022]\].

![IP pathway KOs have reduced IP6 and IP5 levels and have a loss of infectious particle release.\
(A) 33% PAGE gel separating inositol phosphates. Two dilutions of purified 1 M IP6 were used as a standard and had IP5 breakdown products. The number of cells in each sample is indicated. (B) IP6 quantification of panel A in ng per million cells and μM. (C) Relative IP5 quantification normalized to the HEK293FT control. (D) Experimental timeline. (E) Percent infectious particle release normalized to HEK293FT cells. Student's t-test was used for pair-wise comparison (n = 4, \*\*\* p \< 0.001, error bars = mean + SD). (F) Representative western blot of experiments from panel D. Full-length HIV-Gag (pr55) and GAPDH loading control are presented on the left panels. Virus released into media is presented in the middle panel. A longer exposure of the virus release blot was also taken and presented on the right panel.](ppat.1008646.g002){#ppat.1008646.g002}

Next, we measured infectious HIV-1 particle production from HEK293FT cells and its two derivative knockout lines. An HIV-1^ΔEnv^ provirus containing a GFP reporter (HIV-CMV-GFP) was co-transfected with a VSV-G expression construct into the three cell lines in parallel, and the media was titered on fresh target cells ([Fig 2D](#ppat.1008646.g002){ref-type="fig"}). As we reported previously, infectious particle production from the IPPK-KO cell line was reduced \~20--100 fold compared to HEK293FT cells ([Fig 2E](#ppat.1008646.g002){ref-type="fig"}) \[[@ppat.1008646.ref010]\]. The IPMK-KO cells displayed a more modest \~5-fold reduction in infectious particle production that corresponded with the residual IP6 levels found in the cells ([Fig 2E](#ppat.1008646.g002){ref-type="fig"}). We then tested whether the block in infectious virus particle production was due to a block in virus release or to reduced infectivity of released virus. To accomplish this, we measured the pr55 Gag/p24 CA protein level in producer cells and the supernatant. Western blots with an antibody against p24 CA revealed that HEK293FT, IPPK-KO, and IPMK-KO cells all produced full length pr55 Gag at relatively equal levels ([Fig 2F](#ppat.1008646.g002){ref-type="fig"}, left). However, p24 CA released into the supernatant was barely detectable from the IPPK-KO cells, while media from IPMK-KO cells contained normal p24 levels ([Fig 2F](#ppat.1008646.g002){ref-type="fig"}, middle and right). If pr55 Gag is not released as virus particles, one might expect to see a buildup of Gag in transfected cells. In the representative blot shown, pr55 Gag in the IPPK-KO cells was slightly reduced relative to GAPDH. However, because some viral transduction occurs within the transfected cells that amplifies the Gag production, this could explain why cells that are able to support infectious particle production appear to express slightly higher Gag levels. Together, the western blot data show that loss in infectious particle production primarily correlates with a loss in viral release.

Exogenous addition of MINPP1 depletes IP6 and IP5 and is toxic to cells {#sec004}
-----------------------------------------------------------------------

Knock-out of IPPK ablates IP6 in cells while slightly increasing IP5 levels, while knock-out of IPMK leaves residual levels of IP6 and IP5. The finding that low-level infectious particle production still occurs in IPPK-KO cells is consistent with the hypothesis that IP5 can substitute for IP6 in supporting HIV-1 assembly. However, because neither IPPK-KO nor IPMK-KO cells were completely devoid of IP5 and IP6, we could not rule out other explanations. Therefore, we next attempted to make pairwise knockouts of IPPK, IPMK, and ITPK1 (which also contributes to IP5 synthesis \[[@ppat.1008646.ref012],[@ppat.1008646.ref016],[@ppat.1008646.ref021]--[@ppat.1008646.ref027]\]) to further reduce inositol phosphate levels. Numerous attempts failed to yield such double knockouts, likely because loss of the combination of enzymes was lethal. Therefore, as an alternative approach, we attempted to modulate levels of inositol phosphates by overexpressing multiple inositol polyphosphate phosphatase-1 (MINPP1), an enzyme that removes the 3-phosphate from IP6 and IP5 ([Fig 3A](#ppat.1008646.g003){ref-type="fig"}) \[[@ppat.1008646.ref012],[@ppat.1008646.ref036]--[@ppat.1008646.ref038]\]. While removal of 3-phosphate from IP6 results in the production of an alternative species of IP5 (I(1,2,4,5,6)P~5~), this IP5 species has an equatorial hydroxyl group that is likely not favorable for interaction with the lysines in the IP6 binding pocket ([Fig 3A](#ppat.1008646.g003){ref-type="fig"}).

![Addition of multiple inositol polyphosphate phosphatase 1 (MINPP1) removes endogenous IP6 and relevant IP5 species from cells.\
(A) Inositol phosphate pathway showing MINPP1 removal of the 3-position phosphate from IP6, IP5, and IP4. Removal of 3-phosphate from IP6 and I(1,3,4,5,6)P~**5**~ results in an equatorial hydroxyl group. (B) Experimental timeline. (C) 33% PAGE gel separating inositol phosphates. Dilution of purified 1 M IP6 was used as a standard and had an IP5 breakdown product. The number of cells in each sample is indicated. (D) IP6 quantification of panel C in ng per million cells and μM. (E) Relative IP5 quantification of panel C normalized to the HEK293FT control.](ppat.1008646.g003){#ppat.1008646.g003}

We first tested whether inositol phosphates could be modulated in a transient assay. To do this, we generated expression constructs containing cDNAs for IPPK or MINPP1 on a plasmid that also expressed a selectable hygromycin gene. These vectors were individually transfected into HEK293FT cells or IPPK-KO cells, the cells were briefly treated with hygromycin to eliminate untransfected cells, and inositol phosphate levels were directly measured from the surviving cells ([Fig 3B](#ppat.1008646.g003){ref-type="fig"}). In HEK293FT cells, exogenous expression of IPPK increased IP6 levels while decreasing IP5 levels ([Fig 3C--3E](#ppat.1008646.g003){ref-type="fig"}, column 2). In contrast, exogenous expression of MINPP1 reduced, but did not ablate, IP6 and IP5 levels ([Fig 3C--3E](#ppat.1008646.g003){ref-type="fig"}, column 3). IPPK-KO cells had no detectable IP6, but expression of IPPK restored IP6 levels ([Fig 3C--3E](#ppat.1008646.g003){ref-type="fig"}, columns 4--5). Expression of MINPP1 in IPPK-KO cells resulted in a near complete loss of IP5 in addition to the loss of IP6 ([Fig 3C--3E](#ppat.1008646.g003){ref-type="fig"}, column 6). This result demonstrates that exogenous expression of MINPP1 is a viable method of modulating intracellular IP5 levels.

To reduce the inherent variability in transient transfection experiments, we attempted to stably express MINPP1 in IPPK-KO cells. These attempts to stably express MINPP1 resulted in poor recovery under hygromycin in IPPK-KO cells but was tolerated in HEK293FT cells. Previous reports indicated that MINPP1 expression can induce apoptosis \[[@ppat.1008646.ref036]--[@ppat.1008646.ref038]\]. To verify that the low recovery of MINPP1 expressing cells was in fact due to toxicity, we created a retroviral reporter vector in which MINPP1 cDNA was followed by an IRES-EGFP ([Fig 4A](#ppat.1008646.g004){ref-type="fig"}). Cells transduced with this reporter should express both MINPP1 and EGFP, and cell survival can be determined by measuring the number of GFP positive cells over time ([Fig 4B](#ppat.1008646.g004){ref-type="fig"}). HEK293FT cells expressing MINPP1-IRES-GFP or a control (IRES-GFP alone, [Fig 4A](#ppat.1008646.g004){ref-type="fig"}) were maintained in the population over the course of three weeks indicating tolerance of MINPP1 ([Fig 4C and 4D](#ppat.1008646.g004){ref-type="fig"}). However, the majority of IPPK-KO cells expressing MINPP1-GFP were lost over the course of the experiment, consistent with toxicity ([Fig 4C and 4D](#ppat.1008646.g004){ref-type="fig"}). This supports previous reports of a balance of IP6 and IP5 promoting cell viability \[[@ppat.1008646.ref037],[@ppat.1008646.ref038]\]. Importantly, cell death from MINPP1 expression in IPPK-KO cells was not immediate, which allowed a window for testing the effects of MINPP1 expression on virus production.

![Exogenous expression of MINPP1 is toxic in IPPK-KO cells.\
(A) Plasmid map of expression vectors. (B) Experimental timeline. (C) Line plot of a representative experiment. The percentage of cells expressing EGFP over time are normalized to the starting population of EGFP positive cells for each cell line. (D) Bar chart of percent EGFP positive cells on the last day of collection from panel C (day 21). Student's t-test was used for pair-wise comparison (n = 4, \*\* p \< 0.01, \*\*\* p \< 0.001, error bars = mean ± SD).](ppat.1008646.g004){#ppat.1008646.g004}

Exogenous addition of MINPP1 essentially abolishes HIV-1 infectious virus production {#sec005}
------------------------------------------------------------------------------------

Because it was not possible to make a stable IPPK-KO cell line expressing MINPP1, we chose to test the effects of MINPP1 expression on virus production using a transient expression assay. Briefly, HIV-CMV-GFP and VSV-G DNAs were co-transfected into HEK293FT or IPPK-KO cells with either an expression vector containing IPPK cDNA, MINPP1 cDNA, or no insert, and the cells were allowed to produce virus for two days ([Fig 5A](#ppat.1008646.g005){ref-type="fig"}). Infectious virus particles were then titered on HEK293FT cells ([Fig 5A](#ppat.1008646.g005){ref-type="fig"}). As before, infectious particle production was reduced 20-100-fold from IPPK-KO cells ([Fig 5B](#ppat.1008646.g005){ref-type="fig"}). Addition of IPPK to HEK293FT cells had no appreciable effect on this number, but addition to IPPK-KO cells enhanced infectious particle production by approximately 10-fold ([Fig 5B](#ppat.1008646.g005){ref-type="fig"}). Likewise, addition of MINPP1 to HEK293FT cells also had no appreciable effect on infectious particle production, but addition to IPPK-KO cells further reduced infectivity by approximately 10-fold, which approached background levels ([Fig 5B](#ppat.1008646.g005){ref-type="fig"}). Western blotting was again used to determine at which step in infectious virus particle production was blocked ([Fig 5C](#ppat.1008646.g005){ref-type="fig"}). The expression of pr55 Gag in cells was similar among all conditions, indicating that modulation of inositol phosphate levels was not grossly affecting translation levels ([Fig 5C](#ppat.1008646.g005){ref-type="fig"}, top and middle). Exogenous expression of IPPK and MINPP1 did not appear to affect viral release or protein maturation from HEK293FT cells ([Fig 5C](#ppat.1008646.g005){ref-type="fig"}, bottom left). Introduction of IPPK and or MINPP1 into the IPPK-KO did not noticeably alter pr55 Gag expression levels relative to the GAPDH control ([Fig 5D](#ppat.1008646.g005){ref-type="fig"}). However, viral release from IPPK-KO cells varied considerably across the conditions, and the amount of virus released closely tracked with infectious particle production ([Fig 5C](#ppat.1008646.g005){ref-type="fig"}, bottom right; [Fig 5E](#ppat.1008646.g005){ref-type="fig"}, quantification). HIV-1 CA release in IPPK-KO cells, which still express IP5, was greatly stimulated by expression of IPPK cDNA, but CA released was essentially abolished by expression of MINPP1, which removes the IP5. This is in agreement with an earlier report from Mallery *et al*. that showed that viral particle production was reduced in cells lacking IPPK and that the remaining infectious particles produced contained IP5 in place of IP6 \[[@ppat.1008646.ref031]\]. This current data goes further to suggest that the presence of IP6 or IP5 is an absolute requirement for the release of viral particles. However, because there were essentially no virus particles released in the absence of IP5 and IP6, it was not possible to determine if any such particles might have been infectious. Thus, it remains possible that IP5 and/or IP6 also are required at other stages of the viral life cycle.

![IPPK-KO cells expressing MINPP1 have substantial loss in infectious particle production due to a block in viral release.\
(A) Experimental timeline. (B) Bar chart of percent infectious particle release normalized to virus from HEK293FT cells expressing the empty vector. Student's t-test was used for pair-wise comparison (n = 5, \*\*\* p \< 0.001, error bars = mean ± SD). (C) Representative western blot of two experiments from panel B. The rows are full-length HIV-Gag (top), GAPDH loading control (middle), and virus released into media (bottom). A longer exposure was also taken for the blot of released virus. (D) Relative quantification of uncleaved pr55 Gag normalized to GAPDH levels in cell lysate. (E) Relative quantification of p24 Gag in virus released into media.](ppat.1008646.g005){#ppat.1008646.g005}

Depletion of IP6 and IP5 in target cells does not affect susceptibility to HIV-1 infection {#sec006}
------------------------------------------------------------------------------------------

IP6 has been shown to stabilize the lattice of the immature and mature hexamer \[[@ppat.1008646.ref010],[@ppat.1008646.ref029]--[@ppat.1008646.ref031]\]. This stabilization has been proposed to be important for DNA synthesis following the release of the viral core into the cytoplasm of target cells \[[@ppat.1008646.ref029]\]. When the viral core is depleted of IP6 *in vitro*, it breaks down more readily. Thus it has been inferred that after fusion with the target cell, IP6/IP5-lacking virus cannot effectively reverse transcribe the viral RNA to DNA \[[@ppat.1008646.ref029],[@ppat.1008646.ref039]\]. To test if IP6 in the target cell is required for susceptibility to infection, we infected HEK293FT or IPPK-KO cells with virus produced from either HEK293FT or IPPK-KO cells and compared infection levels. If IP6 in the target cell is required for viral infection, one would expect to see a lower viral titer in IPPK-KO cells, regardless of the source of virus. By contrast, if IP6 is required for infection but can be derived from the producer or target cells, one would expect the virus to have a lower relative titer on IPPK-KO cells only when the virus is produced from IPPK-KO cells. In fact, we observed no significant difference in titer on the two types of cells, regardless of the source of the virus ([Fig 6A](#ppat.1008646.g006){ref-type="fig"}). While this experiment demonstrates that IP6 is not required in the target cell for infection, it does not address whether IP5 is perhaps able to substitute for IP6 at this stage of the infection.

![IP6 and IP5 levels in target cells do not affect susceptibility to HIV-1 infection.\
(A) Bar chart of percent infectious particle release normalized to HEK293FT cells. Student's t-test was used for pair-wise comparison (n = 4, \* p \< 0.05). (B) Experimental timeline of the assay. (C) Plasmid map of HIV-1^**ΔEnv**^-CD4. (D) Example flow plots show output from the assay. (E) Bar chart of the ratio of the actual percent double positive cells to the expected double positive cells. The expected percent of double positive cells was calculated from the total percent of red cells and green cells. Student's t-test was used for pair-wise comparison (n = 4, \* p \< 0.05, error bars = mean ± SD).](ppat.1008646.g006){#ppat.1008646.g006}

To test the role of IP5 depletion in susceptibility of target cells, we next transduced the MINPP1-IRES-GFP vector or an empty IRES-GFP control ([Fig 4A](#ppat.1008646.g004){ref-type="fig"}) into HEK293FT or IPPK-KO cells, and then tested their susceptibility to infection ([Fig 6B](#ppat.1008646.g006){ref-type="fig"}). Two days after transduction with MINPP1 IRES-GFP or IRES-GFP, cells were transduced with VSV-G pseudotyped HIV-1^ΔEnv^ virus containing a CD4 reporter ([Fig 6C](#ppat.1008646.g006){ref-type="fig"}). Two days after virus transduction, surface CD4 was stained with an APC-conjugated antibody to score for successful virus transduction ([Fig 6D](#ppat.1008646.g006){ref-type="fig"}). If cells expressing MINPP1 are less susceptible to infection, then the fraction of GFP-positive cells that are also APC positive (virus transduced) should be less than the fraction GFP-negative cells that are APC positive. If they are more susceptible, then the fraction of GFP-positive cells that are also APC positive should be more than the fraction GFP-negative cells that are APC positive. The expected fraction of GFP/APC double positive cells can then be calculated based on the total number of GFP and APC positive cell and compared to the actual number of GFP/APC double positive cells observed ([Fig 6D](#ppat.1008646.g006){ref-type="fig"}, equation). Expression of MINPP1 was found not to alter the susceptibility of HEK293FT or IPPK-KO cells ([Fig 6E](#ppat.1008646.g006){ref-type="fig"}). Together, these data suggest that neither IP6 nor IP5 from target cells is required for viral infection. As before, since we were not able to obtain virus that was devoid of IP5 and IP6, it was not possible to determine if IP5 and/or IP6 from the producer cell is required for core stability during infection.

Beta- and Gamma-retroviruses do not require IP6 or IP5 for infectious virus production {#sec007}
--------------------------------------------------------------------------------------

Different retroviral species vary in Gag lattice structure and viral protein trafficking. The IP6 and IP5 requirement for assembly of other retroviral species can inform the different assembly strategies utilized by retroviruses. With HIV-1 as the model virus, we first tested outgroup retroviral species with our exogenous gene co-transfection system. With expression of IPPK and MINPP1 in HEK293FT cells, the Gammaretrovirus Murine Leukemia Virus (MLV) did not vary in viral output ([Fig 7A](#ppat.1008646.g007){ref-type="fig"}). Infectious MLV particle production from IPPK-KO was reduced a few-fold compared to HEK293FT cells; however, this reduction could not be modulated further by addition of IPPK or MINPP1. Expression of IPPK actually caused a small but statistically insignificant reduction in infectious particle production compared to empty vector ([Fig 7A](#ppat.1008646.g007){ref-type="fig"}). With expression of MINPP1 in IPPK-KO cells, there was no difference in virus output compared to empty vector ([Fig 7A](#ppat.1008646.g007){ref-type="fig"}). These data suggest that the 3-fold reduction in virus particle release with MLV does not reflect a direct IP6 or IP5 requirement.

![Gammaretroviruses and Betaretroviruses do not require IP6 or IP5 as assembly co-factors.\
Bar charts of percent infectious particle release of other retroviral genera normalized to virus from HEK293FT cells expressing the empty vector. (A) The Gammaretrovirus Murine leukemia virus (MLV, n = 4). (B) The Betaretrovirus Mason-Pfizer monkey virus (MPMV, n = 5). (C) Multiple sequence alignment of CA proteins of HIV-1, MLV, and MPMV. Note the lack of K290 and K359 homology in MLV and MPMV.](ppat.1008646.g007){#ppat.1008646.g007}

We next tested the Betaretrovirus Mason-Pfizer Monkey Virus (MPMV). As with HIV-1 and MLV, expression of IPPK and MINPP1 in HEK293FT cells did not affect infectious particle release ([Fig 7B](#ppat.1008646.g007){ref-type="fig"}). Infectious particle production was again slightly decreased from IPPK-KO cells, but neither IPPK nor MINPP1 expression altered this output ([Fig 7B](#ppat.1008646.g007){ref-type="fig"}). As with MLV, these data suggest that MPMV does not have a strict IP6 or IP5 requirement for infectious particle production. Additionally, amino acid sequence alignment between HIV-1, MLV, and MPMV CA proteins shows no homology to the K290 and K359 residues that interact with IP6 and IP5 in HIV-1 ([Fig 7C](#ppat.1008646.g007){ref-type="fig"}) \[[@ppat.1008646.ref010]\].

The MLV and MPMV data suggest that while the slightly slower rate of growth of IPPK-KO cells had overall negative effects on virus output, production of Gag and other viral proteins as well as release of virus is able to proceed despite cytotoxicity, improper cellular signaling, or another cell effect. While there are cytopathic effects of IP5/IP6 depletion from cells ([Fig 4C and 4D](#ppat.1008646.g004){ref-type="fig"}), the inability of IP5/IP6 modulation to affect virus release of MLV and MPMV suggest that the assembly deficiency seen in HIV was due primarily to the absence of the IP5/IP6 from the virion.

The IP6 and IP5 requirement is conserved across primate lentiviruses {#sec008}
--------------------------------------------------------------------

Both outgroups tested are from different retroviral genera than HIV-1. To determine whether IP6 and IP5 are required for other members of the Lentivirus genus, we next tested the primate (macaque) Simian Immunodeficiency Virus (SIV-mac), the feline Feline Immunodeficiency Virus (FIV), and the equine Equine Infectious Anemia Virus (EIAV). In our exogenous gene expression system, SIV had similar outputs to HIV-1 ([Fig 8A](#ppat.1008646.g008){ref-type="fig"}). Infectious particle production was reduced over 20-fold from IPPK-KO cells relative to HEK293FT cells. Importantly, infectious particle production was partially restored with addition of IPPK and precipitously reduced by the addition of MINPP1. As with MLV and MPMV, transfection of IPPK-KO with EIAV and FIV produced about 3-fold fewer infectious virus particles than HEK293FT cells ([Fig 8B and 8C](#ppat.1008646.g008){ref-type="fig"}). However, neither EIAV nor FIV were significantly affected by introduction of IPPK or MINPP1 ([Fig 8B and 8C](#ppat.1008646.g008){ref-type="fig"}). Comparison of the protein sequence alignments shows homology between all four lentiviruses at K290 and K359; however, prolines upstream and downstream of K290 are not conserved for FIV and EIAV ([Fig 8D](#ppat.1008646.g008){ref-type="fig"}). Together, these data point toward an IP6 and IP5 requirement for primate lentiviruses but not lentiviruses of other species.

![IP6 and IP5 are required assembly co-factors for primate lentiviruses.\
Bar charts of percent infectious particle release of lentiviruses normalized to virus from HEK293FT cells expressing the empty vector. (A) Simian immunodeficiency virus from macaques (SIV, n = 8). (B) Feline immunodeficiency virus (FIV, n = 7). (C) Equine infectious anemia virus (EIAV, n = 5). (D) Multiple sequence alignment of CA proteins of HIV-1, SIV, FIV, and EIAV. Note the homology of K290 and K359 in HIV-1 to lysines in SIV, FIV, and EIAV.](ppat.1008646.g008){#ppat.1008646.g008}

We next wanted to determine if the sensitivity observed in infectious particle production is reflected in an assembly assay *in vitro* with purified proteins. We have reported previously that IP6 stimulates assembly of EIAV particles, despite the lack of dependence in infectivity assays \[[@ppat.1008646.ref040]\]. In the case of EIAV, IP6 acts as an enhancer to virus particle release but is not a requirement. We therefore chose to test the stimulation of HIV-1, SIV, FIV, and EIAV in *in vitro* assembly reactions at pH8 and different IP6 concentrations ([Fig 9](#ppat.1008646.g009){ref-type="fig"}). As expected, addition of as little as 5 μM IP6 stimulated robust assembly of immature, spherical virus like particles (VLPs) for HIV-1 and SIV-mac ([Fig 9A, 9B and 9E](#ppat.1008646.g009){ref-type="fig"}). However, FIV and EIAV required higher concentrations of IP6 and showed more moderate effects ([Fig 9C--9E](#ppat.1008646.g009){ref-type="fig"}), consistent with our previous findings \[[@ppat.1008646.ref040]\]. Interestingly, the construct used for EIAV assembly in the absence of IP6 predominantly forms narrow tubes, which we previously showed to be immature-like lattices \[[@ppat.1008646.ref040]\]. However, in the presence of IP6, they formed predominantly spherical VLPs ([Fig 9D and 9F](#ppat.1008646.g009){ref-type="fig"}). Together, these data suggest that IP6 is a requirement for primate lentiviruses and likely acts as an enhancer to promote non-primate lentivirus assembly.

![Addition of IP6 stimulates *in vitro* immature assembly of lentiviruses.\
Representative images at 36000x and 110000x of virus like particles (VLPs) from *in vitro* assembly reactions at pH8. Assembly reactions were performed with 0, 5, or 50 μM of IP6. (A) VLPs from HIV-1 sCASPNC (ectopic Serine preceding CASPNC) assemblies. (B) VLPs from SIV sCASPNC assemblies. (C) VLPs from FIV sCACSPNC assemblies. (D) VLPs from EIAV sCASPNC assemblies. (E) Quantification of spherical VLPs from each virus assembly reaction (n = 4--6). (F) Quantification of tubular VLPs from each virus assembly reaction (n = 5--6). Should include a definition of the box plot.](ppat.1008646.g009){#ppat.1008646.g009}

Discussion {#sec009}
==========

The requirement of IP6 and IP5 for HIV-1 assembly *in vivo* {#sec010}
-----------------------------------------------------------

IP6 has been shown to be an HIV-1 assembly co-factor. The importance of IP6 has been described in HIV-1 assembly, where it promotes both immature Gag and mature CA assembly, as well as during viral entry, where it stabilizes the capsid en route to the nucleus \[[@ppat.1008646.ref010],[@ppat.1008646.ref029],[@ppat.1008646.ref030]\]. Recently, Mallery *et al*. demonstrated that IP5 is incorporated into viral particles from cells deficient in IP6 production \[[@ppat.1008646.ref031]\]. While release of virus from their IPPK-KO cells was severely diminished, the infectivity of the limited virus that was released was not reduced \[[@ppat.1008646.ref031]\]. This recapitulated the severe loss in virus particle release found in the IPPK-KO cells of Dick *et al*. \[[@ppat.1008646.ref010]\]. Similarly, production of virus in IPMK-KO cells demonstrated that HIV-1 particles packaged IP6 despite depletion of cellular IP6 and IP5 levels \[[@ppat.1008646.ref031]\]. While these studies show a role for IP6 and IP5, the absolute requirement of these small molecules had not been addressed. Here we demonstrated an absolute requirement for IP6 or IP5 in the production of HIV-1 and SIV-mac particles. Furthermore, IP6 and IP5 production in target cells were not required for susceptibility of the cell to infection.

Knock-out of IPPK and IPMK affects cellular levels of IP6 and IP5 resulting in loss of virus production {#sec011}
-------------------------------------------------------------------------------------------------------

We confirmed the ablation of IP6 pools in the IPPK-KO cell line used in Dick *et al*. \[[@ppat.1008646.ref010]\]. There were, however, slightly elevated levels of IP5 in these cells. Since IP5 can substitute for IP6 *in vitro* and *in vivo* \[[@ppat.1008646.ref031]\], the elevated IP5 could explain the residual virus output from the IPPK-KO cells. Alternatively, IPPK and IP6 have been shown to play roles in many cellular pathways that may have negative effects on virus production. For example, IP6 is involved in the activation of histone deacetylase-1 and mRNA export, with IPPK knock-down causing G1/S phase arrest \[[@ppat.1008646.ref041],[@ppat.1008646.ref042]\]. The IPPK-KO cells proliferate more slowly than HEK293FT cells, in concordance with these data. Thus, ablated IP6 and cell arrest could then negatively impact HIV-1 transcriptional regulation, by maintenance of acetylated histones or by block of genome export. Conversely, IP6 can promote necroptosis by directly binding mixed lineage kinase domain-like (MLKL) allowing for plasma membrane rupture \[[@ppat.1008646.ref022]\]. IP6 ablation in IPPK-KO cells prevented IP6 direct binding and activation of MLKL, thereby inhibiting necroptosis. Since HIV-1 infection has been shown to mediate necroptosis \[[@ppat.1008646.ref043],[@ppat.1008646.ref044]\], ablation of IP6 may push infected cells toward necroptosis and induce cytopathic effects in neighboring HIV-1 infected cells, thus, reducing overall infectious particle production in the population of cells.

In the IPPK-KO cells, less processed Gag was present in the cell. We believe this is primarily due to the inability of Gag to initiate release from the cell. Protease is activated during the release process and at least some of the processed Gag seen in the cells is budded particles that have remained cell associated or been endocytosed by the cell. The lack of p24 in IPPK-KO cell lysate is consistent with Gag never progressing to the step where protease activation occurs.

In our attempt to identify IP5's role in immature assembly, we knocked-out IPMK using a single guide RNA. The resulting IPMK-KO cell line had residual levels of IP6 and IP5, which correlated with an intermediate loss of virus production. Additionally, residual levels of IP6 and IP5 pointed to an alternative pathway for IP5 synthesis. The role of ITPK1 in inositol phosphate metabolism has not been fully resolved \[[@ppat.1008646.ref012],[@ppat.1008646.ref016],[@ppat.1008646.ref021]--[@ppat.1008646.ref027]\]. Since ITPK1 has 5- and 6-kinase activity, this enzyme may compensate for the loss of IPMK ([Fig 1A](#ppat.1008646.g001){ref-type="fig"}). Attempts to produce IPMK-ITPK1 double knockout cells were not successful likely because of lethality. This led us to take the alternative approach of removing residual levels of IP5 and IP6, instead of preventing their biosynthesis.

Transient removal of IP6 and IP5 ablates HIV-1 infectious particle production {#sec012}
-----------------------------------------------------------------------------

Inositol phosphates play key roles in cell signaling and modulation of genes regulating these metabolites can have cytopathic effects on the cell as discussed above. We do see slower proliferation of the IPPK-KO cells and cell death with over expression of MINPP1 in agreement with cytopathic effects. While a possible explanation for the assembly and release defects seen in our experiments is the cytotoxicity with mis-regulation of inositol, we believe the phenotype is primarily due to the absence of IP6 and IP5. In support of this conclusion, we see that background production of the house keeping protein GAPDH is relatively similar across treatments ([Fig 2F](#ppat.1008646.g002){ref-type="fig"} and [Fig 5C](#ppat.1008646.g005){ref-type="fig"}). In addition, viral protein production in the cell is largely unaffected ([Fig 2F](#ppat.1008646.g002){ref-type="fig"} and [Fig 5C](#ppat.1008646.g005){ref-type="fig"}), indicating that the cytopathic effects on the cell do not affect the production of viral proteins. Importantly, other retroviruses (MLV and MPMV) were able to produce and release virus from cells despite IP6/IP5 modulation. Together, these findings provide evidence for IP6/IP5 as the key contributors to the phenotypes we present, not cytopathic effects on the cell.

Transient expression of MINPP1 resulted in substantial loss of IP5 in the IPPK-KO cells. This loss of IP5 correlated with a further decrease in release of infectious virus. This suggests that the residual virus produced from the IPPK-KO cells substituted IP5 for IP6. Mallery *et al*. \[[@ppat.1008646.ref031]\] demonstrated that IP5 can substitute for IP6 and that the released virus is just as infectious per ng of RT as those that utilize IP6; however, they also showed that there was drastic reduction in the amount of virus released. Their data and conclusions additionally showed that Gag is produced from KO cells at similar levels compared to WT, but release of p24 CA is severely impaired from KO cells. The inability of IP6- and IP5-depleted cells to release virus in our transient gene expression system is in agreement with the findings of Mallery *et al* \[[@ppat.1008646.ref031]\] and further provides evidence for an absolute requirement for IP6 or IP5 in immature virus assembly.

While MINPP1 is known to remove only the phosphate at the 3-position on the inositol ring, this position is on the equatorial plane of myo-inositol ([Fig 3A](#ppat.1008646.g003){ref-type="fig"}) \[[@ppat.1008646.ref036]--[@ppat.1008646.ref038]\]. Furthermore, removal of 3-phosphates results in dead-end inositol phosphate species according to the currently known metabolism pathway \[[@ppat.1008646.ref012]\]. These inositol phosphate species are currently not known to be re-phosphorylated to produce relevant IP6 and IP5 for HIV-1 assembly \[[@ppat.1008646.ref012]\]. The negative charge on the equatorial plane is critical for coordinating the lysine ring of the MHR (major homology region) K290 in HIV-1 as demonstrated by the low number of VLPs in assembly reactions with IP4 \[[@ppat.1008646.ref010]\]. It is likely that the residual IP5 detected with MINPP1 addition to IPPK-KO cells corresponds to IP5 species that have equatorial hydroxyls and are not efficiently utilized by lentivirus assembly ([Fig 3A](#ppat.1008646.g003){ref-type="fig"}).

Depletion of IP6 and IP5 in target cells does not affect susceptibility to infection {#sec013}
------------------------------------------------------------------------------------

Mature HIV-1 particles use IP6 to stabilize the Fullerene cone capsid structure. IP6 also has been implicated in hexamer pore interactions with dNTPs, required for reverse transcription, and for trafficking to the nuclear envelope \[[@ppat.1008646.ref010],[@ppat.1008646.ref029],[@ppat.1008646.ref030],[@ppat.1008646.ref039]\]. Therefore, it seemed possible that IP6 and IP5 levels could affect these viral interactions during viral entry, and thus cell susceptibility to infection. Here, we demonstrated cells depleted of IP6 and IP5 are just as susceptible to infection as HEK293FT cells. Our data suggest that if IP6 or IP5 are required for viral entry and trafficking, the molecules incorporated during viral assembly are sufficient for this process. We speculate that while cells devoid of IP6 and IP5 cannot produce infectious HIV-1 particles, mutants in Gag might be able to do so. Such mutants might be used to address the dynamics of IP6-capsid interactions at early stages of infection. Furthermore, since inositol phosphates have been implicated in immune responses such as RIG-I signaling \[[@ppat.1008646.ref045]\], there may be signaling responses that can affect the rate of infection. More detailed kinetic studies would be required to investigate this possibility.

Requirement of IP6 and IP5 is conserved across primate lentiviruses and likely acts as an enhancer for assembly of non-primate lentiviruses {#sec014}
-------------------------------------------------------------------------------------------------------------------------------------------

Here, we showed that the requirement for IP6 or IP5 in infectious particles production is a phenotype of primate lentiviruses. *In vitro*, we see stimulatory effects for FIV and EIAV with addition of IP6, which supports the notion that IP6 acts as an enhancer for assembly of non-primate lentiviruses. This may seem at odds with the recent report from Mallery *et al*. \[[@ppat.1008646.ref031]\] where they showed an effect on FIV virus production from IPMK- and IPPK-KO cells. However, that study also found a more pronounced phenotype with HIV-1 than with FIV, and the 3-fold reduction shown with FIV is consistent with the 3-fold decrease that we report here. Further, while we see an enhancement of HIV infectious particle production upon reintroduction of IPPK to the IPPK-KO cell line, we saw no such enhancement with FIV. The Mallery *et al*. study did not explore gene replacement \[[@ppat.1008646.ref031]\]. This suggests that the lower titers with FIV seen in both our data and Mallery et al. (2019) are likely due to cytopathic effects of the IPPK gene KO and not a requirement of IP6/IP5.

We recently showed that EIAV utilizes IP6 as an enhancer for assembly *in vitro* \[[@ppat.1008646.ref040]\]. However, EIAV displayed only a modest 2-fold reduction in infectious particle production from IPPK-KO cells ([Fig 8C](#ppat.1008646.g008){ref-type="fig"}). As stated earlier, there are cellular cytopathic effects with mis-regulation of inositol phosphates. This likely plays an important role in the reduction we see. Addition of exogenous genes did not further modulate EIAV infectious particle production. While *in vitro*, we see a stimulatory effect in EIAV assembly, there is likely a stricter balance of inositol phosphates required for proper assembly of EIAV *in vivo*.

The robust requirement for IP6 or IP5 is conserved across primate lentiviral species. The lower Gag amino acid sequence homology between lentiviruses and retroviruses of other genera correlates with the lack of a phenotype for beta- and gamma-retroviruses in cells with ablated IP6 and IP5 levels. This suggests that either their structural proteins have relatively stable hexagonal lattice structures and do not require a coordinating molecule, or that another small molecule coordinates structural protein assembly. How viruses evolved to use IP6 is still a topic of great interest and should be further studied.

Conclusion {#sec015}
----------

In this study, we present data to show that IP6 or IP5 are an absolute requirement for HIV-1 infectious virus particle assembly. Additionally, this robust requirement is likely conserved across primate lentiviruses, but not for other retrovirus genera. While IP6 at high molar concentrations can stimulate *in vitro* assembly for non-primate lentiviruses, the physiological relevance remains to be determined. Furthermore, IP6/IP5 levels in target cells do not affect susceptibility to infection. Understanding at what point IP6 is incorporated into the forming Gag lattice in the cell, for example nucleating assembly of Gag hexamers, may provide new targets for therapeutics.

Materials and methods {#sec016}
=====================

Plasmid constructs {#sec017}
------------------

All lentiviral vectors for CRISPR/Cas-9 delivery were pseudotyped with VSV-g (NIH AIDS Reagent Program) \[[@ppat.1008646.ref046]\]. CRISPR/Cas-9 vectors were derived from the plasmid lentiCRISPRv2 (a gift from Feng Zhang; Addgene plasmid \# 52961; <http://n2t.net/addgene:52961>; RRID:Addgene_52961) \[[@ppat.1008646.ref032]\]. Guide sequences for *IPPK* and *IPMK* were obtained from the Human GeCKOv2 CRISPR knockout pooled libraries (a gift from Feng Zhang; Addgene \#1000000048, \#1000000049) \[[@ppat.1008646.ref032]\]. Briefly, nucleotide bases as per the lentCRISPRv2 protocol were added to the specific sequences for *IPPK*, *IPMK*, and *ITPK* from the pool, and were cloned into the lentiCRISPRv2 plasmid ([Table 1](#ppat.1008646.t001){ref-type="table"}) \[[@ppat.1008646.ref032]\]. The CRISPR/Cas9 vector with guide sequences were delivered via the packaging vector psPAX2 (a gift from Didier Trono; Addgene plasmid \# 12260; <http://n2t.net/addgene:12260>; RRID:Addgene_12260).

10.1371/journal.ppat.1008646.t001

###### Primers used for cloning.

![](ppat.1008646.t001){#ppat.1008646.t001g}

  Primer                    Sequence
  ------------------------- -------------------------------------------
  IPPK guide RNA forward    caccgAACAGCGCTGCGTCGTGCTG
  IPPK guide RNA reverse    aaacCAGCACGACGCAGCGCTGTTc
  IPMK guide RNA forward    caccgTCACCTCCCACTGCACCAAA
  IPMK guide RNA reverse    aaacTTTGGTGCAGTGGGAGGTGAc
  ITPK1 guide RNA forward   caccgGGCCCTGCTCCTCGATCGGC
  ITPK1 guide RNA reverse   aaacGCCGATCGAGGAGCAGGGCCc
  IPPK cDNA forward         cctcgtacgcttaatATGGAAGAGGGGAAGATGGACG
  IPPK cDNA reverse         gcggaattccggatcTTAGACCTTGTGGAGAACTAATGTGC
  MINPP1 cDNA forward       cctcgtacgcttaattaaATGCTACGCGCGCCCGGC
  MINPP1 cDNA reverse       gcggaattccggatccTCATAGTTCATCAGATGTACTG
  IPPK flanking forward     GAAATGTGTGCCACTGTGTTTA
  IPPK flanking reverse     ATGATGGACACACCACTTTCT
  IPMK flanking forward     AGGCTAGAATTAGATAACCAAGAAGAG
  IPMK flanking reverse     GAGGAAGTCATGCAGAGACAATA
  ITPK1 flanking forward    CCTGGCCTGTTGACACTATT
  ITPK1 flanking reverse    GAGCCATTTCTCCAGACTATACC

All cDNA vectors were packaged with a CMV-MLV-Gag-Pol expression plasmid (kindly provided by Walther Mothes, Yale University) pseudotyped with VSVg (NIH AIDS Reagent Program) \[[@ppat.1008646.ref046]\]. Primers for cDNA amplification were ordered from IDTDNA ([Table 1](#ppat.1008646.t001){ref-type="table"}). Primers consisted of 3' sequences matching the coding sequences for *IPPK* and *MINPP1* and had 15 base pair overhangs for InFusion cloning (Clonetech, PT3669-5; Cat. No. 631516) into expression plasmid pQCXIH (Clonetech) using the restriction sites PacI and BamHI. The MINPP1 IRES GFP was made by replacing the hygromycin resistance cassette from the previous clone with IRES-GFP via InFusion cloning.

All retroviruses were pseudotyped with VSV-g (NIH AIDS Reagent Program) \[[@ppat.1008646.ref046]\]. HIV-1 ^ΔEnv^ consisted of NL4-3-derived proviral vector with a 3' cytomegalovirus (CMV) driven green fluorescent protein (GFP) and defective for Vif, Vpr, Nef, & Env (kindly provided by Vineet Kewal-Ramani, National Cancer Institute-Frederick). HIV-1-CD4 was made by replacing GFP from the previous clone with CD4 via InFusion cloning. SIV^ΔEnv^ consisted of the Gag-Pol expression plasmid pUpSVOΔΨ and the reporter vector plasmid pV1eGFPSVO (kindly provided by Hung Fan, University of California-Irvine). FIV ^ΔEnv^ consisted of the Gag-Pol expression plasmid pFP93 and the reporter vector plasmid pGinsin (kindly provided by Eric Poeschla, University of Colorado-Denver) \[[@ppat.1008646.ref047]\]. EIAV ^ΔEnv^ consisted of the Gag-Pol expression plasmid pONY3.1 and the reporter vector plasmid pONY8.0-GFP (kindly provided by Nicholas D. Mazarakis, Imperial College-London) \[[@ppat.1008646.ref048]\]. MPMV ^ΔEnv^ consisted of an Env-deficient expression plasmid pSARM into which our lab engineered a CMV driven GFP reporter before the 3' LTR (kindly provided by Eric Hunter, Emory University). MLV ^ΔEnv^ consisted of the CMV-MLV-Gag-Pol expression plasmid (kindly provided by Walther Mothes, Yale University) and the reporter vector plasmid pQCXIP-GFP (a gift from Michael Grusch (Addgene plasmid \# 73014; <http://n2t.net/addgene:73014>; RRID:Addgene_73014)).

Cells and knock-out of cellular genes {#sec018}
-------------------------------------

The HEK293FT cell line was obtained from Invitrogen and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 10 mM nonessential amino acids, and 1% minimal essential medium vitamins. Knock-out cell lines were obtained via transduction of HEK293FT cells with lentiCRISPRv2 containing the guide sequences targeting a 5' exon on all known splice variants of the *IPPK* and *IPMK* genes ([Table 1](#ppat.1008646.t001){ref-type="table"}). 48 hrs post transduction culture media was replaced with media containing 1 μg/mL puromycin and incubated until complete death of non-transduced control cells (\~48--72 hrs). Clonal isolates (\> 10) were obtained by sparse plating of surviving cells on a 10 cm dish and allowing colonies to grow. Colonies were then picked and expanded in new plates. KO was verified by amplification of genomic DNA flanking the CRISPR target site ([Table 1](#ppat.1008646.t001){ref-type="table"}; 500--600 bp PCR product), direct sequencing of the PCR product, and sequence analysis. Sequences were screened using TIDE (Tracking of Indels by Decomposition; \[[@ppat.1008646.ref049]\]) by comparing Sanger sequence traces of the WT control to the KO. The algorithm not only quantifies major reads, but the underlying background reads and gives p-values for each calculated insertion-deletion. Sequences of clonal isolates were analyzed for mutations that cause frame shifts in the open reading frame that result in premature termination. With the IPPK-KO clone isolates, we saw two distinct sequences diverge after the guide RNA site and is consistent with two alleles. Our lab luckily identified one homozygous clone (a -10 bp deletion) for IPPK-KO. The deletion in this clone causes a premature stop codon immediately upstream (two amino acids) of the guide RNA target site and causes the IPPK gene to be truncated to \~33 amino acids compared to the 492 amino acids of the full length dominate isoform of IPPK. Since the guide RNA targeted a 5' exon of all known splice variants, the other isoforms would be similarly truncated. With the IPMK-KO clonal isolates we saw three distinct sequences diverge from the guide RNA site of our selected IPMK-KO, suggesting three alleles. Such aneuploidy is common in HEK 293 derived cell lines. As can be seen in [Fig 1C](#ppat.1008646.g001){ref-type="fig"}, there were aberrant sequence traces after the break point at the guide RNA site in the IPMK-KO clone. Deep analysis of these traces showed a -10 bp and -1 bp deletion as well as a +1 bp insertion. As these were not multiples of three, the alleles would have all out-of-frame mutations and would truncate IPMK in a similar manner as the IPPK-KO.

Virus production and transductions {#sec019}
----------------------------------

HIV (NL4-3 derived), SIV (mac), EIAV (pony), MLV (Moloney), VLPs were produced by polyethylenimine (PEI, made in house) transfection of HEK293FTs or KO derivatives at 50% confluence with 900 ng of viral plasmids plus VSV-g in a 9:1 ratio \[[@ppat.1008646.ref050]\]. Media containing virus (viral media) was collected two days post transfection. Viral media was then frozen at -80°C for a minimum of 1 hr to lyse cells, thawed in a 37°C water bath, precleared by centrifugation at 3000 x g for 5 min and supernatant collected. Aliquots after titration were stored at -80°C and subsequently used for assays.

Viral media was titered on HEK293FT cells by serial dilution. Viral media was then added to fresh HEK293FT cells at low MOI to prevent infection saturation. Infected cells were collected and assayed via flow cytometry. Infections were then normalized to percent of infections in WT HEK293FT cells and presented as relative particle production.

Separation of inositol phosphates {#sec020}
---------------------------------

Inositol phosphates were separated and quantified as per Wilson *et al*. \[[@ppat.1008646.ref035]\]. All steps were performed on ice and 100 μL of 100 μM IP6 and 100 μL of 10 μM IP6 standards were treated in parallel as a control. Briefly, inositol phosphates were extracted from counted cells (HEK293FT and IPPK-KO) by suspension in 1 M perchloric acid. Cells were pelleted and supernatants were transferred to tubes containing 4 mg of TiO~2~ beads (GL Sciences Inc., Titansphere; Cat. No. 5020--75000) in 50 μL 1 M perchloric acid to bind inositol phosphates. Washed inositol phosphates bound to TiO~2~ beads were eluted with 10% ammonium hydroxide, beads pelleted, and supernatant collected. Supernatant was then concentrated to 10uL and pH neutralized by SpeedVac centrifugation.

A 33% PAGE large gel (16 x 20 cm; TBE pH 8, Acrylamide:Bis 19:1, SDS) was cast and pre-run for 30 min at 500 V. The entirety of concentrated samples (10 μL) was mixed with 50 μL bromophenol blue loading buffer (6X Buffer). The samples were then run over night at 4°C at 1000 V until the loading dye had traveled through one-third of the gel. The gel was then stained with toluidine blue for 30 min and destained. Gels were then imaged. Molar concentrations were calculated assuming a cell diameter of 15 μM \[[@ppat.1008646.ref051]\]

Surface labeling of cells {#sec021}
-------------------------

Cells were washed with PBS and treated with 10 mM EDTA. Cells were then collected with PBS, centrifuged at 300 x g for 5 min, and supernatant removed. Cells were blocked with 5% goat serum in PBS for 30 min on ice. Cells were centrifuged at 300 x g for 5 min and supernatant removed. Anti-CD4 antibody conjugated to Alexa-Fluor 555 was applied to cells at 1:100 in 1% goat serum in PBS for 1 hr. Cells were then washed 3 x with PBS, suspended in 400 μL of PBS, and 100 μL of 10% paraformaldehyde (PFA) added to fix cells. After incubation for 20 min on ice, cells were centrifuged at 300 x g for 5 min and supernatant was removed. Cells were resuspended in 200 μL of PBS and analyzed via flow cytometry.

Flow cytometry {#sec022}
--------------

Cells in 6- and 12-well format were washed with PBS and treated with 10 mM TrypLE™ Express Enzyme (Gibco; Cat. No. 12605028). Cells were then collected with PBS and added to 10% PFA to a final concentration of 4%. After 10--20 min incubation at room temperature, the cells were centrifuged at 300 x g for 5 min, supernatant removed, and 300 μL of PBS added. Cells were analyzed for fluorescence using an Accuri C6 flow cytometer.

Western blot {#sec023}
------------

Supernatant collected after preclearing thawed media containing virus was pelleted via centrifugation through a 20% sucrose cushion (20% sucrose, 100 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.5) for 2 h at 30000 x g at 4°C. Supernatant and sucrose buffer were aspirated off, leaving a small amount of sucrose buffer so as not to aspirate the viral pellet (\~10 μL). Ten μL of 2x sample buffer (50 mM Tris, 2% sodium dodecyl sulfate \[SDS\], 20% glycerol, 5% β-mercaptoethanol) was added to pelleted virus and heated to 95°C for 5 min before loading.

Cell samples were washed with PBS and trypsinized with 10 mM EDTA. Cells were then collected with PBS, centrifuged at 300 x g for 5 min, and supernatant removed. Twenty μL of RIPA extraction buffer with protease inhibitor was then added to each sample \[[@ppat.1008646.ref052]\]. The samples were then kept on ice and vortexed every 5 min for 20 min, followed by centrifugation at 10000 rpm for 10 min at 4°C. Supernatant was then transferred to a new tube, 20 μL of 2x sample buffer added, and heated to 95°C for 5 min before loading.

Samples were separated on a 10% SDS-PAGE gel and transferred onto a 0.22 μm pore size polyvinylidene difluoride (PVDF) membrane. Membranes were blocked for 1 hr at room temperature with 5% nonfat dry milk in PBS-tween. Membranes were then incubated with anti-HIV p24 hybridoma medium was diluted 1:500 (HIV-1 p24 hybridoma \[183-H12-5C\], obtained from NIH AIDS Reagent Program) from Bruce Chesebro \[[@ppat.1008646.ref053]\] for 1 hr at room temperature. After blots were washed with PBST (3 x for 5 min), horseradish peroxidase (HRP)-conjugated secondary antibody was applied at 1:10,000 to all blots. After 1 hr, blots were again washed 3x with PBST and imaged. Horseradish peroxidase-linked anti-mouse (A5278), was obtained from Sigma. Luminata Classico Western HRP substrate (Millipore) was used for visualization of the membranes with a chemiluminescence image analyzer (UVP BioSpectrum 815 Imaging System).

Protein purification and in vitro assembly of CANC protein {#sec024}
----------------------------------------------------------

Protein purification, in vitro assembly, and imaging of all lentiviral CANC proteins was performed as previously described in Dick *et al*. \[[@ppat.1008646.ref040]\] and briefly here. 50 μM protein purified from bacteria was mixed with 10 μM GT25 oligo without or with 5 μM or 10 μM IP6. 30 μL assembly reactions were dialyzed against 2 mL buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 2 mM TCEP, without or with 5 μM or 10 μM IP6. 4 hrs post dialysis, assembly reactions were adjusted to 200 μL, spotted onto formvar/carbon grids, stained with 2% uranly acetate, and imaged on a FEI Morgagni transmission electron microscope.

Data analysis {#sec025}
-------------

Flow cytometry data was analyzed using FlowJo™ software \[[@ppat.1008646.ref054]\]. Values for fluorescence were exported to Excel spreadsheet. Images were analyzed using Fiji (ImageJ) \[[@ppat.1008646.ref055]\]. Western blot images were converted to 8-bit, Fiji's gel analysis tools used to calculate density, and values exported to an Excel spreadsheet. VLPs from electron micrographs were quantified manually using Fiji's cell counting tool and values recorded in an Excel spreadsheet. Values from Excel spreadsheets were formatted for statistical analysis via R \[[@ppat.1008646.ref056]\] and exported to CSV format. RStudio was used to analyze data and create figures \[[@ppat.1008646.ref057]\]. UGene was used for plasmid cloning, sequence analysis, and chromatogram image generation \[[@ppat.1008646.ref058]\]. Final figures were prepared using Inkscape \[[@ppat.1008646.ref059]\].
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\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: This paper presents data to document the importance of IP6 and IP5 in primate lentivirus particle production. KOs of kinases involved in their synthesis, and overexpression of phosphatases to reduce them, are used to test for effects on virion yield. Previous work has shown that KO of IPPK (no IP6, high IP5) led to large reductions in virus yield. This was confirmed here (Fig 2F). Overexpression of the phosphatase in the KO line, only feasible transiently, reduced IP5 levels to undetectable and further lowered yield to near zero (Fig 5C), indicating that either IP6 or IP5 can support some virus production. Experiments also showed that IP5/6 levels do not matter for the early steps of infection. Non lentivirus, and even nonprimate lentiviruses, do not show the same requirements. Most of the data is clear. There is particularly good analysis and presentation of the IP intermediates and pathways.

Reviewer \#2: In this paper, the authors extend previously published work on the role of inositol-pentakisphosphate (IP5) and inositol-hexakisphosphate (IP6) on HIV-1 assembly and particle infectivity. Consistent with a recent publication (ref 31) they report that cells in which inositol-pentakisphosphate 2-kinase (IPPK) has been knocked out express no detectable IP6 but elevated levels of IP5, and display severely reduced virus release but not reduced specific particle infectivity. The authors transiently express multiple inositol polyphosphate phosphatase-1 (MINPP1) in IPPK-KO cells to nearly ablate IP5 and IP6, essentially abolishing virus particle production. The authors also show that HIV-1 infectivity is not significantly reduced when IP5/IP6 are depleted from target cells. Finally, the authors show that primate lentiviruses, but not non-primate lentiviruses or other retroviruses (beta and gamma), are dependent on IP5/IP6 for their assembly.

Characterization of the role of IP6 in HIV-1 assembly and infectivity has been moving at a rapid pace, and the current study provides useful new information. In particular, use of KO cells as targets, and the use of MINPP1, are novel. I have only a couple minor comments for improvement of the MS.

Reviewer \#3: Ricana et al. present further evidence as to the importance of IP5/IP6 in HIV particle assembly and release. It has been previously shown that knockout of IPPK which is required to get IP6 results in a reduction in virus production. The question they address here is whether residual IP5 can substitute for the IP6. They are not able to block the production of both IP5 and IP6 in cells as least one of these is required for viability. However, they were able to transiently have cells highly depleted for both IP5 and IP6 by generating a 293 cell line knocked out for IPPK and then further depleting IP5 by transient transfection of the phosphates MINPP1. In these cells, HIV production was abolished. This is the case for SIVmac but not some other lentiviruses and not for MLV suggesting that the requirement is a property of primate lentiviruses.

This is a well written paper with clear figures. The experiments are expertly done and the data are clear and convincing. The study presents a nice complete story.

The main question here is that of significance and novelty. In 2018, in collaboration with the Volker Vogt lab, the authors published an elegant study in Nature showing that IP6 served as a cofactor for HIV assembly and showed cryo-EM showing the molecule sitting at the face of the Gag hexamer structure. In addition, Mallery et al have shown that IP5 can promote assembly of particles in vitro. What's new here seems to be just that if you totally deplete both IP5 and 6 you get a strong block to virion production. It is novel, but not unexpected. Yet, it is a worthwhile finding as it shows how important it is to have one of these sitting in right place on the hexamer. It's also significant with respect to drug discovery as it shows that molecules that act on that site of capsid would be valuable. Simply blocking production of these molecules is not going to be possible.

Major points

1\. It is hard to get from the paper what the major finding is. It is not fair to conclude that IP5 is required for particle production, as knock-out of the molecule has no effect in normal cells. An accurate statement of their findings might be that in the absence of IP6, IP5 can partially substitute. It is important that the authors make a clear statement as to the point of their study. This should be in the abstract and in the Discussion.

2\. Mallery et al. recently showed that IP5 can substitute for IP6. Isn't that at odds with the results here in which it is shown that IP5 only poorly substitutes for IP6? The authors need to clarify whether this is a discrepancy or can be explained.

3\. One wonders whether the transient depletion of IP5/6 from the cells is having other effects that lead to the failure to assemble. These molecules play critical signaling roles in cells. Are the authors sure that the assembly deficiency is due to the absence of the molecules from the virion and not from another effect on the cell?

4\. Fig. 2F. IPPK knock-out prevents virus release. In these cells there should be a buildup of Gag Pr55. In fact, the cells show less Gag precursor. That would suggest that it's not a block to assembly, but a block to Gag synthesis.

5\. The earlier Mallery et al. Cell Reports paper shows that FIV requires IP6. That seems to be at odds with the results here. The authors need to comment on this apparent discrepancy.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: Major points:

The tests for the effects on virion production are minimal here (really it's all Fig 5C). We probably need error bars on this key experiment.

Some of the presentation is a little confusing in its relationship to the earlier work. As the authors point out (line 106), "Knockouts of the IPPK and IPMK genes have both been reported to reduce the production of infectious HIV-1 particles in vivo." Thus, work very similar to what we see here is in the literature (Cell Rep. 2019;29(12):3983 and Nature. 2018;560: 509). Still, there are some aspects of the present study that are new: We do get a deeper understanding of the relative importance of IP5 vs. IP6. And issues such as requirements for virus entry are addressed. Nonprimate viruses are examined. The paper acknowledges the earlier work, but doesn't make it totally clear what is old news and what is truly new information -- we need a sharper transition.

I think we need to be given more data on the nature of the KO mutations being studied here. 293 cells are notoriously aneuploid, and often have 3 or 4 or more copies of various chromosomes. Thus the KO clones generated need to be characterized to know that all alleles were genuinely mutated, to know what the alleles are, and to be sure that no wild-type alleles or partially active alleles are still lurking. This all becomes more crucial when there is the potential for partial activity to explain the findings. On line 429 of methods -- how many clones were tested to find good KOs, and how many clones were tested for virus (I gather only one)? How many alleles were examined in each cell clone? What were the alleles -- any in-frame mutations? "Direct sequencing" of PCR products is not adequate, because it only gives the majority allele. There is a broad assumption here that CRISPR is perfect every time, and this is definitely not true.

Reviewer \#2: N/A

Reviewer \#3: none

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: Minor points:

1\. While the MINPP1 overexpression after transient transfection was apparently successful in eliminating detectable IP5 and IP6, giving a window to examine effects on virus, there is always the concern that the cells are potentially very sick -- as indicated by the inability to recover stable transfectants. Given this situation, how confident can we be that the inhibition of virus production is not a problem with the general metabolic state of the cells, caused by the low IP5/6? One pretty good answer is the near normal virion release of MLV and MPMV. This point could be made more forcefully.

2\. In the title, maybe viral particle "release" is the wrong word -- it probably isn't release per se that requires these compounds. Better would be viral particle "production" or something else. This is true elsewhere (l. 155 etc.).

3\. In the abstract, line 31, one of the middle sentences would be clearer if it were changed to something like "...but transient expression of the enzyme multiple inositol polyphosphate

phosphatase-1 (MINPP1) in IPPK-KOs...."

4\. line 154ff: It's probably too hard to measure low levels of CA, but it would be nice if the level of physical particles could be quantitatively compared with infectious virus, to confirm that the low levels of released virus are of normal infectivity. It's certainly roughly true.

5\. line 281: "neither virus" is unclear. The authors mean EIAV and FIV, but since in the last sentence MLV and MPMV are also mentioned, this needs to be reworded.

6\. Some comments on the processing of Gag might be warranted. In the KO, Gag is apparently no longer processed. Would a protease minus Gag behave any differently in terms of virion yield in any of the experiments? Some speculation could be included.

Reviewer \#2: 1. As mentioned above, several key findings, e.g., the ability of IP5 to substitute for IP6 in virus assembly, and the lack of an infectivity defect in virus produced from IPPK KO cells (which unfortunately was not properly tested in the authors' Nature paper because they measured particle infectivity, not particle assembly/release), were made in ref 31 but this seems to be a bit downplayed here.

2\. The EIAV results would appear to contrast with what these authors recently published (Dick et al., PLoS Pathog 2020). This should be clarified for the reader.

Reviewer \#3: 1. Fig. 2. B and C. Remove shading from histogram bars.

2\. Fig. 2 E. Error bars should be made more visible.

3\. Fig. 4B. typo on "transduce" should be "transduced".

4\. Fig. 5B. the log scale on the Y axis showing the tick marks looks weird. Also in other figures. Remove this.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

[Figure Files:]{.ul}

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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Dear Dr. Johnson,

We are pleased to inform you that your manuscript \'Primate lentiviruses require Inositol hexakisphosphate (IP6) or inositol pentakisphosphate (IP5) for the production of viral particles\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Ronald C. Desrosiers

Associate Editor
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Reviewer Comments (if any, and for reference):
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Dear Dr. Johnson,

We are delighted to inform you that your manuscript, \"Primate lentiviruses require Inositol hexakisphosphate (IP6) or inositol pentakisphosphate (IP5) for the production of viral particles,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,
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